Tarsons Products Limited

NSEI:TARSONS Stock Report

Market Cap: ₹25.1b

Tarsons Products Valuation

Is TARSONS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • PM vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TARSONS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TARSONS (₹467.85) is trading above our estimate of fair value (₹1.26)

Significantly Below Fair Value: TARSONS is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for TARSONS?

Other financial metrics that can be useful for relative valuation.

TARSONS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.6x
Enterprise Value/EBITDA24.8x
PEG Ratio1.5x

Price to Earnings Ratio vs Peers

How does TARSONS's PE Ratio compare to its peers?

The above table shows the PE ratio for TARSONS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average35.1x
INNOVACAP Innova Captab
37.6xn/a₹31.2b
WINDLAS Windlas Biotech
19.6xn/a₹10.3b
524394 Vimta Labs
26.9xn/a₹11.1b
SYNGENE Syngene International
56.3x20.4%₹281.6b
TARSONS Tarsons Products
45.6x31.3%₹25.1b

Price-To-Earnings vs Peers: TARSONS is expensive based on its Price-To-Earnings Ratio (45.6x) compared to the peer average (35.1x).


Price to Earnings Ratio vs Industry

How does TARSONS's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.3%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.3%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: TARSONS is expensive based on its Price-To-Earnings Ratio (45.6x) compared to the Asian Life Sciences industry average (28.9x).


Price to Earnings Ratio vs Fair Ratio

What is TARSONS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TARSONS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio45.6x
Fair PE Ratio33.7x

PM vs Fair Ratio: TARSONS is expensive based on its Price-To-Earnings Ratio (45.6x) compared to the estimated Fair Price-To-Earnings Ratio (33.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TARSONS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹467.85
₹644.00
+37.7%
13.8%₹750.00₹511.00n/a4
Feb ’25₹492.55
₹647.00
+31.4%
15.9%₹760.00₹511.00n/a3
Jan ’25₹527.40
₹644.25
+22.2%
13.9%₹760.00₹511.00n/a4
Dec ’24₹471.70
₹637.40
+35.1%
13.3%₹760.00₹511.00n/a5
Nov ’24₹467.65
₹661.60
+41.5%
9.9%₹775.00₹590.00n/a5
Oct ’24₹526.00
₹671.40
+27.6%
9.2%₹775.00₹590.00n/a5
Sep ’24₹526.70
₹691.75
+31.3%
7.5%₹775.00₹636.00n/a4
Aug ’24₹611.65
₹716.75
+17.2%
13.0%₹875.00₹636.00n/a4
Jul ’24₹602.25
₹710.50
+18.0%
11.7%₹850.00₹636.00n/a4
Jun ’24₹570.85
₹740.25
+29.7%
9.6%₹850.00₹666.00n/a4
May ’24₹565.40
₹786.75
+39.1%
8.6%₹900.00₹722.00n/a4
Apr ’24₹532.15
₹786.75
+47.8%
8.6%₹900.00₹722.00n/a4
Mar ’24₹591.00
₹808.33
+36.8%
8.1%₹900.00₹755.00n/a3
Feb ’24₹686.25
₹841.67
+22.6%
13.3%₹1,000.00₹755.00₹492.553
Jan ’24₹694.45
₹851.67
+22.6%
14.8%₹1,030.00₹755.00₹527.403
Dec ’23₹701.95
₹851.67
+21.3%
14.8%₹1,030.00₹755.00₹471.703
Nov ’23₹762.90
₹862.00
+13.0%
11.9%₹1,000.00₹756.00₹467.653
Oct ’23₹815.55
₹862.00
+5.7%
11.9%₹1,000.00₹756.00₹526.003
Sep ’23₹780.55
₹862.00
+10.4%
11.9%₹1,000.00₹756.00₹526.703
Aug ’23₹814.40
₹865.00
+6.2%
12.7%₹1,020.00₹775.00₹611.653
Jul ’23₹700.10
₹865.00
+23.6%
12.7%₹1,020.00₹775.00₹602.253
Jun ’23₹733.90
₹865.00
+17.9%
12.7%₹1,020.00₹775.00₹570.853
May ’23₹695.30
₹847.00
+21.8%
9.5%₹960.00₹781.00₹565.403
Apr ’23₹704.90
₹847.00
+20.2%
9.5%₹960.00₹781.00₹532.153

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.